AstraZeneca Iressa Focus Is Sequential Therapy After INTACT Studies Fail
Executive Summary
AstraZeneca is looking at Iressa monotherapy as an element of sequential chemotherapy regimens for solid tumors following the failure of the INTACT studies, VP-Medical Director of Oncology George Blackledge told an Aug. 19 conference call
You may also be interested in...
Iressa Approval Upholds Standard For Oncology Subpart H Approvals – FDA
The Iressa approval upholds the current standard of approval for oncology drugs under the Subpart H accelerated approval regulations, FDA maintains
Iressa Approval Upholds Standard For Oncology Subpart H Approvals – FDA
The Iressa approval upholds the current standard of approval for oncology drugs under the Subpart H accelerated approval regulations, FDA maintains
Iressa Postmarketing Trial Modeled On Tarceva Phase III Under Consideration
FDA is understood to be considering the design of OSI/Genentech/Roche's Tarceva Phase III trial in refractory non-small cell lung cancer as a model for a postmarketing trial for AstraZeneca's Iressa